Edition:
United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

6.20USD
23 Feb 2018
Change (% chg)

$0.14 (+2.31%)
Prev Close
$6.06
Open
$6.07
Day's High
$6.31
Day's Low
$6.06
Volume
13,940
Avg. Vol
160,733
52-wk High
$12.80
52-wk Low
$3.10

Chart for

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)

Overall

Beta: 2.86
Market Cap(Mil.): $40.63
Shares Outstanding(Mil.): 6.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Pain Therapeutics Resubmits New Drug Application For Remoxy ER

* PAIN THERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR REMOXY® ER, AN ABUSE-DETERRENT, EXTENDED-RELEASE DRUG CANDIDATE FOR THE TREATMENT OF CHRONIC PAIN

Feb 13 2018

BRIEF-Pain Therapeutics Signs On Demand Sales Agreement With JonesTrading Institutional Services

* PAIN THERAPEUTICS SAYS ON FEB 8, CO ENTERED INTO AN ATM CAPITAL ON DEMAND SALES AGREEMENT WITH JONESTRADING INSTITUTIONAL SERVICES LLC - SEC FILING

Feb 09 2018

BRIEF-Pain Therapeutics Inc QTRLY ‍Net Loss Per Share $0.37​

* PAIN THERAPEUTICS INC QTRLY ‍NET LOSS PER SHARE $0.37​ Source text: [http://bit.ly/2nGTz7J] Further company coverage:

Feb 05 2018

BRIEF-Pain Therapeutics Reports Positive Results From Nasal Abuse Potential Study With Remoxy

* PAIN THERAPEUTICS REPORTS POSITIVE TOP-LINE RESULTS FROM NASAL ABUSE POTENTIAL STUDY WITH REMOXY™

Jan 09 2018

BRIEF-Pain Therapeutics Reports Positive Regulatory Meeting For Remoxy

* PAIN THERAPEUTICS REPORTS POSITIVE REGULATORY MEETING FOR REMOXY™

Dec 18 2017

BRIEF-Pain therapeutics reports Q3 loss per share $0.40

* Pain therapeutics reports third quarter 2017 financial results

Nov 01 2017

BRIEF-Pain Therapeutics announces upcoming meeting with FDA

* Pain Therapeutics - ‍U.S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain​

Oct 30 2017

BRIEF-Pain Therapeutics announces successful Phase I clinical study for PTI-125

* Pain Therapeutics announces successful Phase I clinical study for PTI-125

Oct 24 2017

BRIEF-National Institute on Drug Abuse awards Pain Therapeutics $2.2 mln grant

* National Institute on Drug Abuse awards Pain Therapeutics $2.2 million grant Source text for Eikon: Further company coverage:

Sep 18 2017

Competitors

Earnings vs. Estimates